Hemgenix now approved, Paul Perreault plans his exit from CSL; LianBio president hands in resignation
→ As CSL trends upward, Paul Perreault will soon step down, putting one of his lieutenants in the top spot.
Paul McKenzie, the COO at the Australian pharma since 2019, will become CSL’s chief executive on March 6, while Perreault lends a hand in an advisory capacity for six more months after the transition takes effect. McKenzie owns Big Pharma experience from Merck, Bristol Myers Squibb and J&J’s Janssen, and was Biogen’s EVP of pharmaceutical operations & technology before CSL came calling.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.